ONLINE SUPPLEMENTARY MATERIAL

| 2 | Alternative inert gas washout outcomes in patients with primary ciliary dyskinesia |
|----|---|
| 3 | |
| 4 | Sylvia Nyilas; Anne Schlegtendal; Florian Singer; Myrofora Goutaki; Claudia E. Kuehni; Carmen |
| 5 | Casaulta; Philipp Latzin; Cordula Koerner-Rettberg |
| 6 | |
| 7 | |
| 8 | |
| 9 | |
| 10 | |
| 11 | |
| 12 | |
| 13 | |
| 14 | |
| 15 | |
| 16 | |
| 17 | |
| 18 | |
| 19 | |

Methods

2

1

Lung function assessment

4

3

- 5 Nitrogen multiple breath washout
- 6 The main outcome variable to assess global VI was the LCI, first moment ratio (M_1/M_0) and second
- 7 moment ratio (M_2/M_0) . Standard LCI was calculated from the ratio of cumulative expired volume
- 8 (CEV) divided by functional residual capacity (FRC), determined at 1/40th washout which equals 2.5%
- 9 of normalized starting N_2 end-tidal concentration (LCI_{2.5%}). M_1/M_0 and M_2/M_0 were calculated as
- described (1): The normalized end-tidal N₂ concentration is plotted against the number of consecutive
- lung turn overs (TO = CEV/FRC), the area under this washout curve depicts the Moment (M) 0.
- Multiplying the N_2 concentration values by TO and TO² gives M_1 and M_2 , respectively. The higher the
- moment the more weight is given to the tail of the washout. Ratios of MR₁ and MR₂ over M₀ were
- calculated, M_1/M_0 and M_2/M_0 , which thus relate overall VI to VI from slowly ventilated lung regions
- 15 (tail of the washout curve).
- 16 LCI_{5%} was calculated from 1/20th or 5% of the normalized starting N₂ concentration(2). Scond* was
- calculated between the 0th and 3rd TO excluding the slope III value of the first breath (3). Sacin and
- 18 Sacin*, estimates of acinary VI, were derived from the first slope III value accounting for conductive
- 19 VI as recommended (3). The Scond* and Sacin* indices were proposed in more advanced disease
- where the progression of SIII values may form a plateau early after the 3^{rd} TO and not after the 6^{th} TO
- as usual. Besides this physiological consideration, the number of required breaths is decreased.

- 23 Single breath washout
- 24 The tidal SBW tests were performed using the same setup (Exhalyzer D). According to the ERS/ATS
- 25 consensus, we repeated the measurement three times to obtain the average slope III values. After
- 26 relaxed tidal breathing was established, measurements took one tidal in- and expiration from and back
- 27 to FRC while the tracer gases were washed in and out. The double tracer gas (DTG) mixture contained
- 28 26.3% He, 5% SF6, 21% oxygen (O2) and balanced N2 (Singer, Stern et al. 2013). The total molar

mass of this gas mixture is equal to air; therefore molar mass changes during washout reflect ventilation distribution of the tracer gases. During the DTG in/expiration and the following inspiration, we recorded molar mass with a side-stream USFM, tidal flows with a mainstream USFM, and carbon dioxide and O2 signals. The molar mass signal measured in side-stream mode (MMss) during ambient air breathing was used to calibrate the pre-test CO2 signal, i.e. to transform the pre-test CO2 signal by linear regression modelling into an additional molar mass signal (calculated molar mass signal (MMcalc)). By "subtracting" MMcalc from the raw MMss during expiration of the DTG, the molar mass test signal reflecting the agglomerated SF6 and He washout pattern was obtained. The DTG expirogram (MMss-MMcalc) was plotted against expired volume. Duration of SBW testing was calculated by summing testing time with waiting time (10 breath) between tests. One measurement required a maximum of 60 seconds. During one breath the patient in- and exhaled the double-tracer gas (SF₆ and He) from FRC and back to FRC without any forced manoeuvre. Between DTG-SBW tests, at least 10 breaths of room air were required. The S_{III}-DTG was multiplied with tidal volume to normalize for physiological differences in breaths (7). We used the software Spiroware 3.1.6 (Eco Medics AG, Duernten, Switzerland) and LungSim 4.10.3 (NM GmbH, Thalwil, Switzerland) for SBW analysis.

17

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

Results

19

20

21

22

23

24

25

26

27

28

18

Success rate of gas washout measurements

Two patients had to be excluded from the study, because they performed only one valid N_2 -MBW measurement. Thirty patients with PCD performed two and 17 performed three successful N_2 -MBW measurements. Seven patients with PCD performed two and 28 at least three successful DTG-SBW. One patient was excluded from Scond and Sacin calculation, another patient was excluded only from Sacin calculation due to irregular breathing, diminishing S_{III} calculation quality. Due to software problems we had to exclude 10 patients from the Scond*, 10 patients from the Sacin* calculation. Fourteen patients from S_{III} -DTG calculation (figure E1) had to be excluded due inadequate DTG gas mixture. In the group of healthy controls 24 children performed three and 13 performed two successful Online Data Supplement

- 1 N₂-MBW measurements. Twenty-nine children performed three and eight at least two successful
- 2 DTG-SBW. No child had to be excluded from the DTG-SBW measurements. Due to irregular
- 3 breathing we had to exclude nine children for the analyses of Scond, Sacin, Scond* and Sacin*,

4 respectively.

5

Legend to the figures

2

1

- 3 **Figure E1** Flow-diagram of inclusion of patients in the gas washout measurements.
- 4 49 patients with PCD performed N₂-MBW and DTG-SBW. Two patients had to be excluded from the
- 5 study, because they performed only one valid N₂-MBW measurement. Due to technical issues we had
- 6 to further exclude the same 10 patients from the Scond* and Sacin* calculation and 14 patients from
- 7 the S_{III}-DTG calculation. After breath quality control two patients were excluded from the Sacin and
- 8 one from the Scond calculation due to strong irregular breathing pattern and infeasible $S_{\rm III}$ calculation.
- 9 Graph was drawn by using CONSORT diagram (8).

10

11 Figure E2

- Association between LCI_{2.5%} and Scond in 46 patients (black points) with primary ciliary
- dyskinesia (PCD) given in z-scores. Fitted values are shown by the black line. The grey
- background denotes the 95% confidence interval.

15

16

Figure E3

- 17 Association between LCI_{2.5%} [z-score] and S_{III}-DTG [z-score] in 35 patients (black points) with
- primary ciliary dyskinesia (PCD). Fitted values are belonging to the black line. The grey background
- denotes the 95% confidence interval.

20

21

Figure E4

- 22 Association between Scond [z-score] and FEV₁ [z-score] in 46 patients (black points) with primary
- 23 ciliary dyskinesia (PCD). Fitted values are belonging to the black line. The grey background denotes
- the 95% confidence interval.

| 1 | |
|-------------|--|
| 2 | Figure E5 |
| 3 4 5 | Association between Scond* [z-score] and FEV ₁ [z-score] in 38 patients (black points) with primary ciliary dyskinesia (PCD). Fitted values are belonging to the black line. The grey background denotes the 95% confidence interval. |
| 6 | |
| 7 | |
| 8 | |
| 9 | |
| 10 | |
| 11 | |
| 12 | |
| 13 | |
| 14 | |
| 15 | |
| 16 | |
| 17 | |
| 18 | |
| 19 | |
| 20 | |
| 21 | |
| 22 | |
| 23 | |
| 24 | |
| 25 | |

References

1

- 2 1. Robinson PD, Goldman MD, Gustafsson PM. Inert gas washout: theoretical background and clinical
- 3 utility in respiratory disease. *Respiration*. 2009;78:339-55.
- 4 2. Yammine S, Singer F, Abbas C, et al. Multiple-breath washout measurements can be significantly
- 5 shortened in children. *Thorax*. 2013;68:586-7.
- 6 3. Verbanck S, Paiva M, Schuermans D, et al. Acinar and conductive ventilation heterogeneity in
- 7 severe CF lung disease: back to the model. *Respir Physiol Neurobiol*. 2013;188:124-32.
- 8 4. Singer F, Stern G, Thamrin C, et al. A new double-tracer gas single-breath washout to assess early
- 9 cystic fibrosis lung disease. *Eur Respir J.* 2013;41:339-45.
- 10 5. Singer F, Stern G, Thamrin C, et al. Tidal volume single breath washout of two tracer gases--a
- practical and promising lung function test. *PLoS One*. 2011;6:e17588.
- 6. Abbas C, Singer F, Yammine S, et al. Treatment response of airway clearance assessed by single-
- breath washout in children with cystic fibrosis. *J Cyst Fibros*. 2013;12:567-74.
- 14 7. Robinson PD, Latzin P, Verbanck S, et al. Consensus statement for inert gas washout measurement
- using multiple- and single- breath tests. *Eur Respir J.* 2013;41:507-22.
- 16 8. Schuller JC, Mayer M, Lanz D, et al. A novel diagram and complement to the CONSORT chart for
- presenting multimodal clinical trials. *Contemp Clin Trials*. 2009;30:201-4.

18

19

Table E1 Demographic parameters of healthy controls and patients with PCD

| Characteristics | Healthy controls | PCD |
|--------------------------|----------------------------------|-----------------------------------|
| | (n = 37) | $(\mathbf{n} = 49)$ |
| Male/Female | 18/19 | 19/30 |
| Age (years) | 14.3 ± 1.4 , range (4 to 42) | 14.7 ± 6.6 , range (11 to 18) |
| Height (cm) | $163 \pm 9.73^{+}$ | $152 \pm 19.6^{+}$ |
| Weight (kg) | 54 ± 12.3 | 48 ± 17.5 |
| BMI (kg/m ²) | 20 ± 3.4 | 20 ± 3.7 |

Baseline characteristics of healthy controls and primary ciliary dyskinesia (PCD) patients.

Values are expressed as absolute values (mean \pm SD), except male/female. ⁺Only the height differed significantly between healthy controls and PCD, p<0.05. P-values are calculated by Student's t test.

Table E2 Detailed description of PCD diagnostic data of the ten PCD patients with normal TEM results

| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
|------------------------------------|---------|---------|---------|------------|------------|--------------|------|--------|-----|------|
| normal TEM | X | X | Х | х | x | x | X | x | Х | Х |
| typical PCD phenotype ^a | х | X | х | x | x | x | x | x | Х | х |
| situs inversus | | | х | x | | | | | | |
| situs inversus in a sibling | х | X | | | | x | | | | |
| abnormal IF | lack of | lack of | lack of | lack of | abnormal | | | | | |
| | DNAH5 | DNAH5 | DNAH5 | CCDC11, | DNAH5 | | | | | |
| | | | | DNALI1 | | | | | | |
| HVM | | | | | | | | | | |
| - dyskinestic | х | Х | | x | х | | Х | x | Х | X |
| - immotile | | | Х | | | x | | | | |
| genetic analysis with PCD | | | | CCDC11 | DNAI1 | DNAH5 | | | | |
| defect identified | | | | homozygoes | homozygous | homozygous | | | | |
| | | | | , - | | +DNAH11 | | | | |
| | | | | | | heterozygous | | | | |
| positive family history of | х | Х | | | | x | | x | | |
| PCD (in a sibling) | | | | | | | | | | |
| nasal NO below cut off | X | Х | Х | | х | х | Х | | Х | X |
| (<77nl/min) | | | | | | | | | | |
| nasal NO value (nl/min) | 29,30 | 29,54 | 18,48 | 251,53 | 16,40 | 12,21 | 8,90 | 185,46 | 2,3 | 7,69 |

^a Typical symptoms of PCD were defined as neonatal onset airway symptoms, recurrent lower respiratory tract infections, chronic productive cough, blocked nose, recurrent sinusitis, recurrent otitis media.

Table E3 Detailed description of diagnostic data of the ten PCD patients without available TEM

| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
|-----------------------------|-----|---|---|---|---|---|-------|-------|-------|----|
| typical PCD phenotype | X | X | X | X | X | X | X | X | X | X |
| situs inversus | X | X | X | | | | | X | X | |
| situs inversus in a sibling | | | | | | | | | X | |
| abnormal IF | | | | | | | | | X | |
| HVM (nearly) immotile* | · X | X | X | X | X | X | X | X | X | |
| HVM hyperkinetic* | | | | | | | | | | X |
| genetic analysis with | 1 | | | | | | DNAH5 | DNAH5 | ARMC4 | |
| PCD defect identified | | | | | | | | | | |
| positive PCD family | / | | | X | X | | | | | |
| history | | | | | | | | | | |
| nasal NO below cutoff or | f x | X | X | X | X | X | X | X | X | X |
| 77nl/min | | | | | | | | | | |

^{*}HVM showed congruent results on at least two occasions (for immotile cilia) or three occasions (for hyperkinetic ciliary beating pattern).

TABLE E4 Intra-test variability (CV) in patients with PCD and healthy controls who performed three trials.

| Indices | Healthy controls | PCD | p-value |
|-----------------------|---------------------|---------------------|---|
| | | | for comparison PCD and healthy controls |
| LCI _{2.5%} | 4.6 (0.4 to 10.7) | 5.5 (1.4 to 15.4) | 0.44 |
| LCI _{5%} | 3.7 (0.7 to 9.6) | 4.4 (0.8 to 10.9) | 0.40 |
| M_1/M_0 | 3.7 (0.3 to 8.4) | 4.5 (0.9 to 11) | 0.29 |
| M_2/M_0 | 8.6 (0.5 to 20.5) | 9.9 (0.4 to 27.3) | 0.47 |
| Scond | 55.7 (2.5 to 113.9) | 24.2 (2.7 to 96.4) | 0.002 |
| Scond * | 75.5 (2.8 to 134.4) | 37.9 (2.0 to 111.5) | 0.004 |
| Sacin | 61 (6.1 to 268.7) | 32.6 (2.1 to 138.5) | 0.14 |
| Sacin* | 48.6 (0.8 to 120.6) | 38.3 (0.3 to 121) | 0.07 |
| S _{III} -DTG | 41.9 (6.9 to 238) | 23.9 (4.3 to 76.4) | 0.08 |
| | | | |

Coefficient of variation data are expressed in mean (range). PCD (primary ciliary dyskinesia). $LCI_{2.5\%}$, lung clearance index 2.5%; $LCI_{5\%}$, lung clearance index 5%; M_1/M_0 , M_2/M_0 , moment ratio; Scond/Sacin, Scond*/Sacin* and S_{III}-DTG, normalized phase III slope indices (see text for explanation). Significant differences are marked as bold. Student's t test was used, as appropriate.

TABLE E5 Intra-test variability in patients with PCD and healthy controls who performed two trials.

| Indices | Healthy controls | PCD |
|-----------------------------|--------------------|---------------------|
| $	ext{LCI}_{2.5\%}$ | 5.2 (2.8 to 7.6) | 6.8 (3.4 to 10.1) |
| LCI _{5%} | 4.2 (1.6 to 6.7) | 6.4 (4.3 to 8.6) |
| $\mathbf{M_1/M_0}$ | 4.2 (1.3 to 7.2) | 5.9 (3.1 to 8.8) |
| $\mathbf{M}_2/\mathbf{M}_0$ | 8.8 (3.1 to 14.6) | 11 (5.9 to 16) |
| Scond | 56 (29.1 to 83) | 42.6 (33.5 to 52) |
| Scond * | 300.4 (74 to 534) | 49 (37.9 to 60.2) |
| Sacin | 28.6 (9.7 to 47.4) | 29.7 (18.5 to 40.8) |
| Sacin* | 71.4 (2.5 to 58.5) | 37.6 (26.9 to 48.3) |
| S _{III} -DTG | 17.6 (4.3 to 30.9) | 44.8 (-1.8 to 91.3) |

Intra-test variability data are expressed in mean (95% Conf. Interval). PCD (primary ciliary dyskinesia). $LCI_{2.5\%}$, lung clearance index 5%; M_1/M_0 , M_2/M_0 , moment ratio; Scond/Sacin, Scond*/Sacin* and S_{III} -DTG, normalized phase III slope indices (see text for explanation).

Table E6 Association between FEF₂₅₋₇₅ and different gas washout variables in z-scores

| Indices | Coefficient | 95 % CI | R ² | p-value |
|-----------------------|-------------|---------------|----------------|---------|
| LCI _{2.5%} | -0.2 | -0.3 to -0.2 | 0.5 | <0.001 |
| LCI _{5%} | -0.3 | -0.4 to -0.2 | 0.4 | <0.001 |
| M_1/M_0 | -0.3 | -0.4 to -0.2 | 0.4 | <0.001 |
| M_2/M_0 | -0.2 | -0.2 to -0.09 | 0.4 | <0.001 |
| Scond | -0.2 | -0.5 to 0.04 | 0.06 | 0.088 |
| Scond* | -1.0 | -1.3 to -0.6 | 0.5 | <0.001 |
| Sacin | -0.1 | -0.3 to -0.02 | 0.1 | 0.020 |
| Sacin* | -0.5 | -0.9 to -0.1 | 0.2 | 0.014 |
| S _{III} -DTG | 0.6 | 0.2 to 1.0 | 0.2 | 0.006 |

Linear regression between FEF_{25-75} (forced expiratory flow 25–75%) and different gas washout indices: : lung clearance index, $LCI_{2.5\%}$; 2.5%; lung clearance index 5%, $LCI_{5\%}$; moment ratio, M_1/M_0 , M_2/M_0 ; Scond/Sacin, Scond*/Sacin* and S_{III} -DTG, normalized phase III slope indices (see text for explanation). Significant values are marked in bold. Results are derived from linear regression analysis.